KDM6A and colorectal carcinoma: A separate study by Wang et al. (2020) demonstrated that KDM6A/B silencing or inhibition with GSK-J4 sensitised CRC cells to another chemotherapeutic agent oxaliplatin and co-administration of GSK-J4 and oxaliplatin suppressed tumour growth in an oxaliplatin-resistant patient-derived CRC xenograft murine model [34].